Investing in Stereotaxis involves standard micro-cap biotechnology and medical device risks, including ongoing operating losses, potential cash burn requirements, and heavy reliance on the successful commercial adoption of its surgical robotics and proprietary catheter systems. Additional vulnerabilities include regulatory approval hurdles, hospital capital expenditure delays for high-tech operating room equipment, fierce competition from major medtech conglomerates, and potential share dilution resulting from capital-raising activities.